A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease

Table 1 Demographics and baseline characteristics

	POM-001 (N = 22)
Mean age (range), years	49.3 (28–58)
Gender, n (%)
Male	14 (64)
Female	8 (36)
Mean weight (range), kg	89.0 (49.2–144.5)
Mean time since initial diagnosis (range), years	5.4 (0.106–25.12)
Mean % predicted MIP ± SD	40.3 ± 24.0
Mean % predicted MEP ± SD	35.5 ± 14.4
Mean MVV ± SD, L/min	68.9 ± 27.5
Mean % predicted FVC upright ± SD	60.9 ± 19.2
6MWT ± SD, meters	352.5 ± 151.1

Abbreviations:
6MWT 6-min walk test, FVC forced vital capacity, MEP maximal expiratory pressure, MIP maximal inspiratory pressure, MVV maximum voluntary ventilation, SD standard deviation

ISSN: 1750-1172